诊断学理论与实践 ›› 2025, Vol. 24 ›› Issue (04): 449-454.doi: 10.16150/j.1671-2870.2025.04.012
马毓, 吴祁红, 亢园园, 洪墨纳, 唐晓峰, 高平进, 许建忠(), 王继光
收稿日期:
2024-12-04
修回日期:
2025-03-06
接受日期:
2025-06-08
出版日期:
2025-08-25
发布日期:
2025-09-09
通讯作者:
许建忠 E-mail:jianzhongxv@outlook.com基金资助:
MA Yu, WU Qihong, KANG Yuanyuan, HONG Mona, TANG Xiaofeng, GAO Pingjin, XU Jianzhong(), WANG Jiguang
Received:
2024-12-04
Revised:
2025-03-06
Accepted:
2025-06-08
Published:
2025-08-25
Online:
2025-09-09
摘要:
目的:比较原发性醛固酮增多症(primary aldosteronism,PA)和原发性高血压(essential hypertension,EH)患者中难治性高血压(resistant hypertension,RH)的临床特征,分析RH的危险因素。方法:收集2010年1月至2014年12月在我院就诊查高血压原因的2 138例连续高血压患者,统计RH患病率,并将其中385例(18.0%)患者为PA组,同时匹配年龄、性别、血压水平一致的385例EH患者(EH组),比较2组中的RH患病率、一般临床资料,分析PA、EH患者中RH与左心室肥厚(left ventricular hypertrophy, LVH)间的关系,采用多元线性回归分析预测RH的危险因素。结果:RH在高血压科住院患者中约占26.0%(556/2 138),而RH患者中有9.2%(51/556)为PA患者。PA组中RH患病率明显低于EH组(13.2%比35.3%,P<0.001)。在PA组中RH患者与非RH患者间的LVH的发生率无统计学差异(59.3%比56.9%);在EH组中,RH患者的LVH发生率远高于非RH的患者(54.3%比30.1%,P<0.05)。多元回归分析显示,诊室收缩压水平、男性及糖尿病是PA患者发生RH的独立危险因素。EH组RH的发生,与年龄、高血压病程、LVH及肌酐水平独立相关(P<0.05)。结论:在住院高血压患者中,RH患病率约为26.0%,在血压水平相当的PA患者和EH患者中,RH在EH患者中的患病率更高,而LVH在PA患者中的发生率更高,与其是否为RH无关。EH组中,RH患者的LVH发生率高于非RH患者。诊室收缩压、男性及罹患糖尿病可预测PA是否为RH的因素。
中图分类号:
马毓, 吴祁红, 亢园园, 洪墨纳, 唐晓峰, 高平进, 许建忠, 王继光. 原发性醛固酮增多症中难治性高血压患者的临床特征分析[J]. 诊断学理论与实践, 2025, 24(04): 449-454.
MA Yu, WU Qihong, KANG Yuanyuan, HONG Mona, TANG Xiaofeng, GAO Pingjin, XU Jianzhong, WANG Jiguang. Analysis of clinical characteristics of patients with resistant hypertension in primary aldosteronism[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(04): 449-454.
表1
PA与EH组中RH患者一般临床资料
Characteristics | PA (n=385) | EH(n=385) | |||||
---|---|---|---|---|---|---|---|
RH (n=51) | Non-RH (n=334) | P | RH (n=136) | Non-RH (n=249) | P | ||
Male/Female | 38/13 | 172/162 | 0.001 | 65/51 | 134/115 | 0.389 | |
Age(years) | 52.2 ± 11.2 | 50.4 ± 11.0 | 0.283 | 54.2± 11.7 | 46.7 ± 14.5 | 0.994 | |
BMI (kg/m2) | 25.8 ± 3.4 | 25.0 ± 3.5 | 0.124 | 26.0 ± 3.3 | 25.2 ± 3.3 | 0.753 | |
Diabetes [n (%)] | 17 (33.3) | 53 (15.9) | 0.004 | 39 (28.7) | 41 (16.5) | 0.004 | |
Hypertension duration (years) | 12.9 ± 8.3 | 10.8± 8.5 | 0.096 | 13.3 ± 10.8 | 7.9 ± 8.3 | <0.001 | |
FBG (mmol/L) | 5.1 ± 1.4 | 4.8 ± 0.9 | 0.143 | 5.0 ± 1.3 | 4.8 ± 1.1 | 0.175 | |
Serum creatinine (μmol/L) | 70.2 ± 14.7 | 67.9 ± 16.8 | 0.296 | 73.5 ± 16.3 | 68.6 ± 16.4 | 0.006 | |
Serum K+(mmol/L) | 3.3 ± 0.4 | 3.2 ± 0.4 | 0.114 | 3.7 ± 0.4 | 3.7 ± 0.4 | 0.972 | |
Triglyceride (mmol/ L) | 1.5 ± 1.2 | 1.1 ± 1.1 | 0.063 | 1.6 ± 1.6 | 1.5 ± 1.2 | 0.379 | |
Total cholesterol (mmol/ L) | 3.8 ± 0.9 | 4.0 ± 0.9 | 0.215 | 4.2 ± 1.0 | 4.3 ± 0.9 | 0.974 | |
LDL(mmol/ L) | 2.1 ± 0.7 | 2.2 ± 0.8 | 0.273 | 2.4 ± 0.8 | 2.3 ± 0.8 | 0.834 | |
HDL(mmol/ L) | 0.5 ± 0.5 | 0.7 ± 0.5 | 0.004 | 0.7 ± 0.5 | 0.7 ± 0.5 | 0.323 | |
PAC(ng/L) | 302.5±191.9 | 313.1 ± 177.2 | 0.711 | 170.7±101.0 | 176.5 ± 90.7 | 0.579 | |
PRA [ng/(ml·h)] | 0.9± 0.9 | 0.7 ± 0.8 | 0.341 | 2.8± 2.3 | 2.9 ± 2.2 | 0.760 | |
Urinary aldosterone (μg/24 h) | 19.1 ± 15.4 | 21.1 ± 14.3 | 0.415 | 7.1 ± 4.3 | 8.7 ± 5.4 | 0.002 | |
SBP in consulting room(mmHg) | 158.3 ± 21.1 | 145.6 ± 19.5 | <0.001 | 150.6 ± 21.2 | 146.8 ± 18.2 | 0.077 | |
DBP in consulting room(mmHg) | 91.8 ± 15.4 | 86.5 ± 12.9 | 0.023 | 88.1 ± 16.1 | 89.6 ± 13.7 | 0.341 | |
24 h mean SBP(mmHg) | 139.5 ± 14.7 | 135.1 ± 13.3 | 0.043 | 137.9 ± 16.4 | 134.1 ± 14.1 | 0.025 | |
24 h mean DBP(mmHg) | 86.0 ± 11.0 | 85.5 ± 8.7 | 0.773 | 84.4 ± 10.4 | 85.6 ± 10.2 | 0.292 | |
Daytime SBP(mmHg) | 143.0 ± 14.9 | 137.5 ± 13.6 | 0.015 | 140.9 ± 16.5 | 138.1 ± 14.6 | 0.093 | |
Daytime DBP(mmHg) | 88.2 ± 11.4 | 87.3 ± 9.0 | 0.594 | 86.5 ± 10.7 | 88.5 ± 10.7 | 0.080 | |
Nighttime SBP(mmHg) | 132.8 ± 17.1 | 129.9 ± 15.4 | 0.253 | 131.1 ± 19.0 | 125.4 ± 15.3 | 0.003 | |
Nighttime DBP (mmHg) | 81.6 ± 11.5 | 81.8 ± 9.6 | 0.922 | 79.4 ± 11.7 | 79.3 ± 10.9 | 0.892 | |
Log NT-proBNP | 1.8 ± 0.5 | 1.7± 0.4 | 0.647 | 1.6 ± 0.5 | 1.4± 0.4 | <0.001 |
表2
多元线性回归分析RH与危险因素的预测
Variables | EH (n=385) | PA (n=385) | ||||
---|---|---|---|---|---|---|
β | t | P value | β | t | P value | |
Age(Years) | 0.005 | 2.339 | 0.020 | |||
LVH | 0.186 | 3.867 | <0.001 | |||
Hypertension duration (Years) | 0.006 | 2.074 | 0.039 | |||
Serum creatinine (μmol/L) | 0.004 | 2.856 | 0.005 | |||
Systolic pressure (mmHg) | 0.003 | 3.362 | <0.001 | |||
Male | 0.084 | 2.465 | 0.014 | |||
Diabetes | 0.013 | 2.341 | 0.020 |
[1] | REINCKE M, BANCOS I, MULATERO P, et al. Diagnosis and treatment of primary aldosteronism[J]. Lancet Diabetes Endocrinol, 2021, 9(12):876-892. |
[2] | CAREY R M, CALHOUN D A, BAKRIS G L, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association[J]. Hypertension, 2018, 72(5):e53-e90. |
[3] |
DAUGHERTY S L, POWERS J D, MAGID D J, et al. Incidence and prognosis of resistant hypertension in hypertensive patients[J]. Circulation, 2012, 125(13):1635-1642.
doi: 10.1161/CIRCULATIONAHA.111.068064 pmid: 22379110 |
[4] | ROSSI G P, ROSSITTO G, AMAR L, et al. Drug-resistant hypertension in primary aldosteronism patients undergoi-ng adrenal vein sampling: the AVIS-2-RH study[J]. Eur J Prev Cardiol, 2022, 29(2):e85-e93. |
[5] | STAVROPOULOS K, IMPRIALOS K P, PATOULIAS D, et al. Impact of primary aldosteronism in resistant hypertension[J]. Curr Hypertens Rep, 2022, 24(8):285-294. |
[6] |
WU Q, HONG M, XU J, et al. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism[J]. Endocrine, 2021, 72(3):835-843.
doi: 10.1007/s12020-021-02606-3 pmid: 33474712 |
[7] | 蒋雄京, 王继光. 难治性高血压——何去何从?[J]. 中国循环杂志, 2022, 37(8):761-765. |
JIANG X J, WANG J G. Refractory hypertension -- where to go?[J]. Chin Circ J, 2022, 37(8):761-765. | |
[8] | PARASILITI-CAPRINO M, LOPEZ C, PRENCIPE N, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension[J]. J Hypertens, 2020, 38(9):1841-1848. |
[9] |
DOUMA S, PETIDIS K, DOUMAS M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study[J]. Lancet, 2008, 371(9628):1921-1926.
doi: 10.1016/S0140-6736(08)60834-X pmid: 18539224 |
[10] |
SANG X, JIANG Y, WANG W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens, 2013, 31(7):1465-1472.
doi: 10.1097/HJH.0b013e328360ddf6 pmid: 24006040 |
[11] |
NOUBIAP J J, NANSSEU J R, NYAGA U F, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients[J]. Heart, 2019, 105(2):98-105.
doi: 10.1136/heartjnl-2018-313599 pmid: 30087099 |
[12] |
BRAMBILLA G, BOMBELLI M, SERAVALLE G, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study[J]. J Hypertens, 2013, 31(10):2018-2024.
doi: 10.1097/HJH.0b013e328363823f pmid: 23838657 |
[13] | CALHOUN D A, JONES D, TEXTOR S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scien-tific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research[J]. Circulation, 2008, 117(25):e510-e526. |
[1] | 侯怡茹, 王敏, 王春花, 陈俞洁. 亚临床原发性醛固酮增多症合并亚临床库欣综合征1例并文献复习[J]. 诊断学理论与实践, 2023, 22(05): 480-485. |
[2] | 王春花, 祁爽, 王敏. 原发性醛固酮增多症合并无痛性心肌梗死一例报告[J]. 诊断学理论与实践, 2020, 19(05): 528-530. |
[3] | 胡哲, 陈歆, 罗芳秀, 初少莉, 王继光. 肾上腺醛固酮和皮质醇共分泌瘤一例报告[J]. 诊断学理论与实践, 2020, 19(05): 525-527. |
[4] | 程艾邦, 李明轩, 陈波, 曹晟, 蒋塨豪, 许建忠, 李燕, 王继光. 化学发光免疫分析法检测血浆肾素、醛固酮在原发性醛固酮增多症诊断中的价值[J]. 诊断学理论与实践, 2020, 19(05): 474-480. |
[5] | 中国高血压联盟. 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020, 19(05): 454-459. |
[6] | 陈歆, 程艾邦, 许建忠, 李燕, 王继光. 中国高血压患者原发性醛固酮增多症的前瞻性筛查研究进展[J]. 诊断学理论与实践, 2020, 19(05): 450-453. |
[7] | 蒋怡然, 王卫庆. 原发性醛固酮增多症的诊治现状及展望[J]. 诊断学理论与实践, 2020, 19(05): 445-449. |
[8] | 康健捷, 苏佩珣, 邓兵梅, 杨红军, 王卓才. 肾上腺腺瘤型原发性醛固酮增多症并发横纹肌溶解症一例[J]. 诊断学理论与实践, 2019, 18(05): 583-584. |
[9] | 蒋怡然, 王卫庆,. 中国原发性醛固酮增多症诊治专家共识解读[J]. 诊断学理论与实践, 2016, 15(04): 350-353. |
[10] | 马燕, 庞小芬, 张之梁, 蔡伟, 任华,. 老年男性原发性高血压患者体内维生素D与骨代谢指标的水平及相关性分析[J]. 诊断学理论与实践, 2015, 14(03): 262-266. |
[11] | 许建忠, 高平进,. 肾神经消融术治疗难治性高血压:现实与展望[J]. 诊断学理论与实践, 2013, 12(03): 259-263. |
[12] | 杜美玲, 杨新春, 蔡军,. 原发性高血压的危险因素和发病机制的新认识[J]. 诊断学理论与实践, 2012, 11(06): 554-557. |
[13] | 刘佳, 杨新春, 蔡军,. 高血压相关的微小RNA研究进展[J]. 诊断学理论与实践, 2012, 11(06): 627-629. |
[14] | 王月妹, 潘雁, 姚蕾,. 原发性高血压患者血清Salusin-α和尿酸的检测及临床意义[J]. 诊断学理论与实践, 2012, 11(03): 299-301. |
[15] | 宋琦, 杜联军, 张欢, 丁蓓, 潘自来, 陈克敏, 方文强,. 多层CT诊断原发性醛固酮增多症的评价[J]. 诊断学理论与实践, 2010, 9(04): 351-354. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||